Estrogen modulation: Tiered testing for human hazard evaluation

被引:12
作者
Carney, EW
Hoberman, AM
Farmer, DR
Kapp, RW
Nikiforov, AI
Bernstein, M
Hurtt, ME
Breslin, WJ
Cagen, SZ
Daston, GP
机构
[1] DOW CHEM CO USA,MIDLAND,MI 48674
[2] ARGUS RES LABS,HORSHAM,PA
[3] MONSANTO CO,ST LOUIS,MO 63198
[4] BIOTOX,RICHMOND,VA
[5] EXXON BIOMED SCI INC,E MILLSTONE,NJ
[6] CIBA GEIGY CORP,TARRYTOWN,NY
[7] EI DUPONT INC,NEWARK,DE
[8] SHELL OIL CO,HOUSTON,TX 77252
[9] PROCTER & GAMBLE CO,CINCINNATI,OH
关键词
tiered testing; estrogenicity; estrogen; antiestrogen; in vitro tests; in vivo tests; hazard identification; endocrine;
D O I
10.1016/S0890-6238(97)00072-5
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recent concerns about the potential of certain chemicals to modulate estrogen-regulated processes have led to questions as to how chemicals should be tested for such effects, Therefore, AIHC has developed a comprehensive, resource-efficient, and flexible tiered strategy for estrogen modulation (EM) testing, Levels of evaluation include Tier 0, in which exposure, along with alerts based on structure-activity, persistence, bioaccumulation, and other data, are assessed to prioritize chemicals for preliminary testing, In Tier I, short term in vitro, ex vivo, and/or in vivo assays are used to obtain a preliminary indication of ERI potential. Among these, an in vivo response assay is considered the most reliable at this time, However, none of these tests are intended for risk assessment, but rather to aid in choosing chemicals for further testing and in guiding the extent of that testing, Tier II is aimed at risk assessment and involves whole animal tests that contain EM-sensitive end points (e.g., two-generation reproduction study). Tier III consists of hypothesis-driven research reserved for situations where targeted research can reduce levels of uncertainty, This tiered approach provides a framework for the strategic and effective application of EM test methods to address specific information needs on a case by case basis. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:879 / 892
页数:14
相关论文
共 90 条
  • [61] *NAS, 1977, NAS PUBLICATION, V1138
  • [62] NICHOLLS PJ, 1986, BREAST CANCER RES TR, V7, P55
  • [63] *OECD, 1981, OECD TEST GUID REP O
  • [64] PAGE NP, 1977, J ENVIRON PATHOL TOX, V1, P161
  • [65] PAGE NP, 1977, ADV MODERN TOXICOLOG, V3
  • [66] Palmer A. K., 1978, RES PROCEDURES DATA, P215
  • [67] PHARMACODYNAMIC AND BIOLOGICAL EFFECTS OF ANTI-ESTROGENS IN DIFFERENT MODELS
    PASQUALINI, JR
    SUMIDA, C
    GIAMBIAGI, N
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1988, 31 (4B) : 613 - 643
  • [68] DOPAMINERGIC AND LIGAND-INDEPENDENT ACTIVATION OF STEROID-HORMONE RECEPTORS
    POWER, RF
    MANI, SK
    CODINA, J
    CONNEELY, OM
    OMALLEY, BW
    [J]. SCIENCE, 1991, 254 (5038) : 1636 - 1639
  • [69] Survey and assessment of mammalian estrogen biological assays for hazard characterization
    Reel, JR
    Lamb, JC
    Neal, BH
    [J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1996, 34 (02): : 288 - 305
  • [70] SCIENTIFIC AND REGULATORY ISSUES RELEVANT TO ASSESSING RISK FOR DEVELOPMENTAL NEUROTOXICITY - AN OVERVIEW
    REES, DC
    FRANCIS, EZ
    KIMMEL, CA
    [J]. NEUROTOXICOLOGY AND TERATOLOGY, 1990, 12 (03) : 175 - 181